denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Hematology Disease Topics & Pathways:
Genomics, Diseases, Lymphoid Malignancies, Biological Processes
Description:
Cancer proteogenomics incorporates methods that integrate mass spectrometry-based measurements of protein abundance and post-translational modifications with genomic, epigenomic and transcriptomic data from preclinical cancer models and patients samples. Such comprehensive multi-omic data provides new biological and diagnostic knowledge that can improve our understanding of malignant transformation and therapeutic outcomes.
This area is new in the field of Plasma Cell Neoplasia and in this session we will discuss how proteogenomic can lead to a better understanding of multiple myeloma (MM) biology and support the development of novel anti-MM therapeutic targets.
Dr. Krönke will discuss the impact of proteogenomic studies on understanding disease progression in plasma cell malignancies. His comprehensive analysis reveals protein-level changes that are not always predictable from genomic or transcriptomic data alone, highlighting the importance of examining protein dynamics in understanding MM pathogenesis. He will further outline how proteogenomic analysis enables the development of new risk stratification models and reveal deregulated proteins and pathways that can be exploited for new therapeutic approaches in MM.
Dr. Maura will discuss how whole genome sequencing can be utilized to reconstruct the genomic landscape and track the temporal evolution of multiple myeloma. These aspects are becoming increasingly relevant, as the timing and mechanisms of plasma cell transformation in the germinal center, along with their progression to MGUS, SMM, and MM, can significantly impact clinical outcomes. He will also explore how comprehensive genomic profiling can identify mechanisms of resistance and predict responses, particularly in the context of immunotherapy using bispecific antibodies and CAR T cells.
Dr. Perna will discuss an integrated pipeline for probing the MM surface proteome (surfaceome) with mass-spectrometry and transcriptomic analyses to identify novel immunotherapeutic targets. She will discuss the contribution that surfaceome makes to MM biology and the pre-clinical development of novel chimeric antigen receptor platforms for MM based on in vitro and in vivo models including patient samples and BCMA-escaped disease. This work may provide a rationale for developing innovative CAR T cells for MM patients.
This area is new in the field of Plasma Cell Neoplasia and in this session we will discuss how proteogenomic can lead to a better understanding of multiple myeloma (MM) biology and support the development of novel anti-MM therapeutic targets.
Dr. Krönke will discuss the impact of proteogenomic studies on understanding disease progression in plasma cell malignancies. His comprehensive analysis reveals protein-level changes that are not always predictable from genomic or transcriptomic data alone, highlighting the importance of examining protein dynamics in understanding MM pathogenesis. He will further outline how proteogenomic analysis enables the development of new risk stratification models and reveal deregulated proteins and pathways that can be exploited for new therapeutic approaches in MM.
Dr. Maura will discuss how whole genome sequencing can be utilized to reconstruct the genomic landscape and track the temporal evolution of multiple myeloma. These aspects are becoming increasingly relevant, as the timing and mechanisms of plasma cell transformation in the germinal center, along with their progression to MGUS, SMM, and MM, can significantly impact clinical outcomes. He will also explore how comprehensive genomic profiling can identify mechanisms of resistance and predict responses, particularly in the context of immunotherapy using bispecific antibodies and CAR T cells.
Dr. Perna will discuss an integrated pipeline for probing the MM surface proteome (surfaceome) with mass-spectrometry and transcriptomic analyses to identify novel immunotherapeutic targets. She will discuss the contribution that surfaceome makes to MM biology and the pre-clinical development of novel chimeric antigen receptor platforms for MM based on in vitro and in vivo models including patient samples and BCMA-escaped disease. This work may provide a rationale for developing innovative CAR T cells for MM patients.